GlassScriptPhysician profile
Sherif Soliman
NPI 1174594915
$3,227.12
in general payments reported to CMS, 2019-2025
30 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $192 · 2021: $52.89 · 2022: $177 · 2023: $985 · 2024: $516 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738 · Education: $37.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.53 |
| Education | $37.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $344.49 | 2022-2025 | Tavneos, Krystexxa |
| Outset Medical INC | $330.53 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $274.64 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $247.55 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $246.97 | 2019-2023 | Korsuva, Veltassa |
| Calliditas Therapeutics US INC. | $234.78 | 2023 | Tarpeyo |
| Glaxosmithkline, LLC. | $213.96 | 2022-2024 | Benlysta, Jesduvroq |
| Bard Peripheral Vascular, INC. | $173.37 | 2019-2023 | Pristine |
| Ardelyx, INC. | $144.04 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $119.12 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $108.41 | 2020-2024 | Acthar, Terlivaz |
| Medtronic, INC. | $107.68 | 2022-2023 | Chameleon |
| Bayer Healthcare Pharmaceuticals INC. | $83.75 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $74.25 | 2019-2021 | |
| Novo Nordisk INC | $71.30 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $62.75 | 2019 | |
| Fresenius USA Marketing, INC. | $53.06 | 2019 | |
| Akebia Therapeutics INC | $40.65 | 2020-2024 | Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.51 | 2025 | Jardiance |
| Daiichi Sankyo INC. | $33.62 | 2019-2023 | Injectafer |
| Horizon Therapeutics Plc | $29.88 | 2022-2023 | Krystexxa |
| Ultragenyx Pharmaceutical INC. | $29.25 | 2023 | |
| Mozarc Medical US LLC | $27.96 | 2024 | Chameleon |
| Genzyme Corporation | $24.07 | 2023 | |
| Apellis Pharmaceuticals, INC. | $23.21 | 2025 | Empaveli |
| Angiodynamics, INC. | $22.85 | 2019 | |
| Avenu Medical INC. | $18.83 | 2020 | |
| Covidien LP | $18.48 | 2019 | |
| Abbott Laboratories | $16.41 | 2019 | |
| Argon Medical Devices, INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherif Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.